The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|March 27, 2020
- Pharmaceutical Technology's In the Lab eNewsletter-04-01-2020
- Volume 15
- Issue 4
Trianni in License Agreement with Nkarta for Trianni Mouse
Author(s)Pharmaceutical Technology Editors
The transgenic mouse R&D platform will support the discovery of fully-human monoclonal antibodies.
Advertisement
Trianni, a San Francisco, CA-based privately held biotech company specializing in antibody discovery technology, has entered into a license agreement with Nkarta, another San Francisco-based biotechnology company specializing in cancer therapeutics based on natural killer cells, for the use of the Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies. The agreement supports Nkarta’s antibody-based therapeutic discovery programs, the companies announced in a March 10, 2020 press release.
“[Trianni] is pleased to add [Nkarta] as a new licensee of the Trianni Mouse,” stated Matthias Wabl, PhD, Trianni’s president and CEO, in the press release. “We are confident that combining “[Trianni]’s powerful antibody discovery platform with [Nkarta]’s unique proprietary technology will facilitate [Nkarta]’s development of novel cell-based therapeutics.”
Source:
Articles in this issue
over 6 years ago
trinamiX Launches a Mobile NIR Spectroscopy Solutionover 6 years ago
Asymmetrex’s New Algorithms Offer Low Cost Rapid Cell Countingover 6 years ago
Integra Now Offers New High-Volume Pipettesover 6 years ago
Thermo Fisher Scientific to Acquire Qiagen for $11.5 BillionAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement